Study of Veltuzumab (hA20) at Different Doses in Patients With ITP
NCT00547066
·
clinicaltrials.gov ↗
PHASE1,PHASE2
Phase
TERMINATED
Status
48
Enrollment
INDUSTRY
Sponsor class
Conditions
Purpura, Thrombocytopenic, Idiopathic
Autoimmune Thrombocytopenic Purpura
Purpura, Thrombocytopenic, Autoimmune
Interventions
BIOLOGICAL:
veltuzumab
Sponsor
Gilead Sciences